Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking strategy to diabetes management. These innovative drugs function by mimicking the physiological actions of GLP-1, a hormone released by the gut in response to meals. By stimulating GLP-1 receptors in the pancreas, these agents boost insulin release and inhibit glucago

The burgeoning landscape of innovative treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a alike therapeutic goal – improving glycemic control and promoting significant weight reduction – they exhibit intriguing variations in